FDA Requires Updated Vision Warnings for All GLP-1 Drugs After Detecting Possible Rare Risk
Key Facts
On November 9, the U.S. Food and Drug Administration said it was requiring the holders of licenses for all GLP-1 receptor agonist drugs to add information about a possible increased risk of non-arteritic anterior ischemic optic neuropathy to the warnings and precautions section of their labels. The decision applies across the drug class and covers medicines used to treat diabetes and reduce weight. The agency said the condition is rare but may cause a sudden, painless decline in vision in one eye and can lead to permanent vision loss. The drugs covered by the announcement include Ozempic and Wegovy from Novo Nordisk, Mounjaro and Zepbound from Eli Lilly, as well as other approved GLP-1 drugs. The FDA framed the action as a warning about a possible increased risk, not confirmation that the drugs cause the condition.
As part of its assessment, the agency cited an analysis covering 126 randomized controlled trials of several drugs in the GLP-1 class. The incidence of optic neuropathy was 6.4 cases per 100,000 person-years among those who received these drugs, compared with 3.8 cases per 100,000 person-years in the comparison group. The comparison group included patients who received a placebo or a glucose-lowering drug from another class. The figures show a difference in the recorded rates between the groups, but do not by themselves establish a causal relationship. The FDA said the cases it studied were a rare outcome, prompting it to add the information to labels rather than describe the risk as confirmed.
The analysis included 134,253 patients, of whom 78,217 used GLP-1 drugs and 56,036 received a comparator drug. Total exposure was 288,879 person-years, including 156,947 person-years among GLP-1 users and 131,932 person-years in the comparison group. In its review of trial data, the FDA identified 15 probable cases of non-arteritic anterior ischemic optic neuropathy. Reporting rates by years of exposure allows comparisons between two groups that differed in size and in the length of participant follow-up. These data provide a numerical basis for the label warning, while the agency continues to describe the risk as possible rather than conclusive.
In a separate retrospective study of FDA data on adults with type 2 diabetes between 2019 and 2024, the result varied according to the comparator drug. The study found no statistically significant increase in the risk of the condition when GLP-1 drugs were compared with SGLT-2 inhibitors; the hazard ratio was 1.19, with a confidence interval of 0.91 to 1.54. By contrast, it found an increase compared with DPP-4 inhibitors, with a hazard ratio of 1.43 and a confidence interval of 1.02 to 2.01. The differing comparisons reflect that the estimated risk in this study was associated with the alternative treatment class. The FDA also cited literature putting the rate of the condition among people over 50 at between 2.3 and 10.2 cases per 100,000 people annually.
The FDA said its review of animal data did not identify a mechanism explaining how the use of GLP-1 drugs could increase the likelihood of the condition. Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. The agency advises patients to contact a health professional immediately if they experience sudden, painless vision loss in one eye, blurred vision or loss of part of their field of vision, or distorted colors. A patient may notice sudden vision loss upon waking. The FDA says doctors should promptly refer anyone suspected of having the condition to an ophthalmologist for evaluation.
For patients who develop optic neuropathy, the FDA recommends considering discontinuation of the GLP-1 drug unless the benefits of treatment clearly outweigh the risks. This is part of the guidance for managing suspected or confirmed cases, while the regulatory action requires an update to the warnings and precautions section across the drugs covered. GLP-1 drugs have approved uses beyond diabetes and weight reduction, including reducing the risk of major cardiovascular events in some adults and reducing the risk of worsening kidney disease in patients with diabetes and chronic kidney disease. At the last available market close before the November 9 announcement, Eli Lilly shares closed at 1,354 dollars and Novo Nordisk shares at 40.31 dollars on November 6, 2026. These prices do not represent share movements during the FDA announcement session.